PharmiWeb46m
Modern Dental Group Shared the Technological Innovation in Dentistry Along the Development of New Quality Productive Forces in CCB International Forum
UTC+8Modern Dental Group Shared the Technological Innovation in Dentistry Along the Development of New Quality Productive Forces in CCB International Forum Modern Dental Group (03600.HK) was invited ...
PharmiWeb2h
Genflow Biosciences PLC Announces Half-year Report
LONDON, UNITED KINGDOM / ACCESSWIRE / September 30, 2024 / Genflow (LSE:GENF) is pleased to announce its half year results for the six-month period ended 30 June 2024.Chairman's StatementIt is with ...
PharmiWeb2h
Formycon and Fresenius Kabi receive FDA approval for FYB202/ OtulfiTM (ustekinumab-aauz)
Regulatory Approval/Market LaunchFormycon and Fresenius Kabi receive FDA approval for FYB202/ OtulfiTM (ustekinumab-aauz) 30.09.2024 / 07:30 CET/CESTThe issuer is solely responsible for the content of ...
PharmiWeb4h
T2D.com Announces That Former NFL Linebacker Alec Ogletree Has Joined the Company as a Co-Founder
Alec Ogletree, former NFL linebacker that in retirement has been investing in and helping build consumer centric companies serving people in need, has joined T2D.com, a company focused on making ...
PharmiWeb2d
Quantum Biopharma Provides Corporate Update
Quantum BioPharma Ltd. (formerly, FSD Pharma Inc.) (NASDAQ:QNTM)(CSE:QNTM)(FRA:0K91) ("Quantum BioPharma" or the "Company"), a biopharmaceutical company dedicated to building a portfolio of innovative ...
PharmiWeb2d
DREAM Pivotal Study Data Presented at the International Surgical Sleep Society 2024 Educational Update
Study resultsDREAM Pivotal Study Data Presented at the International Surgical Sleep Society 2024 Educational Update 27.09.2024 / 22:30 CET/CESTThe issuer is solely responsible for the content of this ...
PharmiWeb2d
Ensysce Biosciences Receives Notice from Nasdaq
SAN DIEGO, CA / ACCESSWIRE / September 27, 2024 / Ensysce Biosciences, Inc. (NASDAQ:ENSC) ("Ensysce" or "Company"), a clinical-stage pharmaceutical company developing innovative solutions for severe ...
PharmiWeb2d
POP Biotechnologies Announces Phase 3 Trial Interim Results Published for COVID-19 Vaccine Based on POP BIO SNAP™
EuCorVac-19 EuCorVac-19, a COVID-19 vaccine candidate developed by EuBiologics and POP Biotechnologies BUFFALO, N.Y., ...
PharmiWeb2d
POP Biotechnologies Announces Phase 3 Trial Interim Results Published for COVID-19 Vaccine Based on POP BIO SNAP(TM)
BUFFALO, NY / ACCESSWIRE / September 27, 2024 / POP Biotechnologies (POP BIO), a Buffalo, NY-based biopharmaceutical company, ...
PharmiWeb2d
LEO Pharma Presents Late-Breaking Results from the…
LEO Pharma A/S, a global leader in medical dermatology, today announced positive results from the Phase 2a Mechanism of Action (MoA) trial, which assessed the mechanistic impact of investigational ...
PharmiWeb2d
CQDM and Epitopea Fund the Development and Validation of CryptoMapTM, a Platform Enabling the Development of RNA-based Immunotherapies
Epitopea, a transatlantic cancer immunotherapy company, and CQDM are proud to announce the launch of a collaborative research project between Epitopea and Université de Montréal (UdeM), a leading ...
PharmiWeb2d
Dupixent approved in the US as the first-ever biologic medicine for patients with COPD
Dupixent is indicated for the approximately 300,000 adults in the US with inadequately controlled COPD and an eosinophilic phenotypeFollowing recent approvals in the EU and China, the US approval is ...